⌕
Mannkind · MNKD · Nasdaq
Tenet 29 · Weak
Compare
$3.96−4.24%At closeTenet 29 · Weak
$3.96−0.18 (−4.24%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Mannkind (MNKD) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Seeking AlphaNov 11, 2026 · 20:13 ET
MannKind's ReadyFlow Launch Keeps The Bull Case Alive

MNKD's ReadyFlow could widen Furoscix's reach into more outpatient settings, which I consider a promising value driver in the long run. Also, their pediatric launch expands Afrezza's market. The main caveat to this is th…

● Seeking AlphaNov 6, 2026 · 05:34 ET
MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript

MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript…

● Defense WorldNov 6, 2026 · 02:15 ET
MannKind Q3 Earnings Call Highlights

MannKind (NASDAQ: MNKD) expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza launches gain tracti…

● Zacks Investment ResearchNov 5, 2026 · 19:31 ET
Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and t…

● Zacks Investment ResearchNov 5, 2026 · 18:46 ET
MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates

MannKind (MNKD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.03 per share a year ago.…

● GlobeNewsWireOct 29, 2026 · 16:01 ETCOMPANY'S OWN WORDS
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after market close on Thursday, …

● MarketBeatOct 20, 2026 · 16:03 ET
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth

MannKind NASDAQ: MNKD Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF, following early safety and…

● BenzingaOct 19, 2026 · 09:16 ET
This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.…

● GlobeNewsWireOct 14, 2026 · 16:01 ETCOMPANY'S OWN WORDS
MannKind to Participate in the Chardan Healthcare Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a panel focused on inn…

● Globe News WireOct 9, 2026 · 20:00 ET
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide Consistent bioavailability, diuresis and natriuresis across injection sites support…

● MarketBeatSep 17, 2026 · 18:02 ET
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum

MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expan…

● BenzingaSep 9, 2026 · 11:34 ET
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule

MannKind Corporation (NASDAQ:MNKD) shares are trading lower on Wednesday as traders react to the company's entry into a licensing and collaboration deal tied to an inhaled, rapid-acting GLP-1 program.…

● GlobeNewsWireSep 9, 2026 · 06:30 ETCOMPANY'S OWN WORDS
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing p…

● GlobeNewsWireSep 2, 2026 · 08:30 ETCOMPANY'S OWN WORDS
MannKind to Present at Upcoming Investor Conferences

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just MNKD · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.